Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jianwei Yun, Zhiping Wu, Guoqing Qi, Tiyun Han & Dekui Zhang. (2021) The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Review of Gastroenterology & Hepatology 15:2, pages 149-157.
Read now
Read now
Andrea Morgner, Joachim Labenz & Stephan Miehlke. (2006) Effective regimens for the treatment of Helicobacter pylori infection. Expert Opinion on Investigational Drugs 15:9, pages 995-1016.
Read now
Read now
M. Hojo, H. Miwa, A. Nagahara, N. Sato. (2001) Pooled Analysis on the Efficacy of the Second-line Treatment Regimens for Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 36:7, pages 690-700.
Read now
Read now
Articles from other publishers (49)
Jian‐Wei Yun, Cui Wang, Yi Yu, Hui‐Mei Xu, Ling‐Zhu Gou, Xiao‐Li Li, Gui‐Rong Yi, Yi‐Ming Lin, Ti‐Yun Han & De‐Kui Zhang. (2022)
High‐dose amoxicillin‐proton pump inhibitor dual therapy as first‐line treatment for
Helicobacter pylori
infection in Northwest China: A prospective, randomised controlled trial
. British Journal of Clinical Pharmacology 89:1, pages 232-241.
Crossref
Crossref
Ferdane Sapmaz, Ismail H. Kalkan, Pinar Atasoy, Sebahat Basyigit & Sefa Guliter. (2017) A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. American Journal of Therapeutics 24:4, pages e393-e398.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
710
725
.
Mojgan Jalalzadeh, Morteza Nazarian, Jamshid Vafaeimanesh & Fatemeh Mirzamohammadi. (2012) Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients. Nephro-Urology Monthly 4:3, pages 571-577.
Crossref
Crossref
Ulrich Schwabe & Dieter PaffrathJoachim Mössner. 2012. Arzneiverordnungs-Report 2012. Arzneiverordnungs-Report 2012
713
743
.
Mohammadreza Seyyedmajidi, Kianoosh Falaknazi, Dariush Mirsattari, Homayoun Zojaji, Mohammad Roshani, Farhad Lahmi, Peyman Gooran Orimi, Maryam Hadizadeh & Mohammadreza Zali. (2011) Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. Arab Journal of Gastroenterology 12:3, pages 150-153.
Crossref
Crossref
Joachim Mössner. 2011. Arzneiverordnungs-Report 2011. Arzneiverordnungs-Report 2011
699
728
.
Joachim Mössner. 2010. Arzneiverordnungs-Report 2010. Arzneiverordnungs-Report 2010
681
709
.
Joachim Mössner. 2009. Arzneiverordnungs-Report 2009. Arzneiverordnungs-Report 2009
653
681
.
Bernhard Glasbrenner & Manfred Kist. 2008. Klinische Infektiologie. Klinische Infektiologie
411
428
.
Joachim Mössner. 2008. Arzneiverordnungs-Report 2007. Arzneiverordnungs-Report 2007
667
694
.
Joachim Mössner. 2008. Arzneiverordnungs-Report 2008. Arzneiverordnungs-Report 2008
661
690
.
L. FISCHBACH & E. L. EVANS. (2007) Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Alimentary Pharmacology & Therapeutics 26:3, pages 343-357.
Crossref
Crossref
Joachim Mössner. 2007. Arzneiverordnungs-Report 2006. Arzneiverordnungs-Report 2006
709
734
.
T. KAWAI, K. KAWAKAMI, M. KATAOKA, S. TAIRA, T. ITOI, F. MORIYASU, Y. TAKAGI, T. AOKI, E. RIMBARA, N. NOGUCHI & M. SASATSU. (2007) Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan. Alimentary Pharmacology & Therapeutics 24, pages 16-22.
Crossref
Crossref
T. KAWAI, K. KAWAKAMI, M. KATAOKA, S. TAIRA, T. ITOI, F. MORIYASU, Y. TAKAGI, T. AOKI, E. RIMBARA, N. NOGUCHI & M. SASATSU. (2006) Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan. Alimentary Pharmacology <html_ent glyph="@amp;" ascii="&"/> Therapeutics Symposium Series 2:1, pages 16-22.
Crossref
Crossref
S. MIEHLKE, K. HANSKY, W. SCHNEIDER-BRACHERT, C. KIRSCH, A. MORGNER, A. MADISCH, E. KUHLISCH, E. BASTLEIN, E. JACOBS, E. BAYERDORFFER, N. LEHN & M. STOLTE. (2006) Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Alimentary Pharmacology and Therapeutics 24:2, pages 395-403.
Crossref
Crossref
Jungi ChoiJoo Young JangJoon Sung KimHwa Young ParkYon Ho ChoeKyung Mo Kim. (2006) Efficacy of Two Triple Eradication Regimens in Children with Helicobacter pylori Infection. Journal of Korean Medical Science 21:6, pages 1037.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
2183
2195
.
Joachim Mössner. 2006. Arzneiverordnungs-Report 2005. Arzneiverordnungs-Report 2005
716
738
.
Miyao Inoue, Keiko Segawa, Sae Matsunaga, Nobuhiro Matsumoto, Mayumi Oda & Toshihiro Yamase. (2005) Antibacterial activity of highly negative charged polyoxotungstates, K27[KAs4W40O140] and K18[KSb9W21O86], and Keggin-structural polyoxotungstates against Helicobacter pylori. Journal of Inorganic Biochemistry 99:5, pages 1023-1031.
Crossref
Crossref
Charlie H Viiala, Helen M Windsor & Barry J Marshall. (2005) CURE RATE OF HIGH DOSE OMEPRAZOLE and AMOXICILLIN THERAPY FOR TREATMENT-RESISTANT HELICOBACTER PYLORI INFECTION. Journal of Gastroenterology and Hepatology 20:4, pages 663-664.
Crossref
Crossref
Selim Aydemir. (2005)
Helicobacter pylori
infection in hemodialysis patients: Susceptibility to amoxicillin and clarithromycin
. World Journal of Gastroenterology 11:6, pages 842.
Crossref
Crossref
Hwang-Huei Wang. (2005)
One-year follow-up study of
Helicobacter pylori
eradication rate with
13
C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy
. World Journal of Gastroenterology 11:11, pages 1680.
Crossref
Crossref
Toshihiro Yamase. (2005) Anti-tumor, -viral, and -bacterial activities of polyoxometalates for realizing an inorganic drug. Journal of Materials Chemistry 15:45, pages 4773.
Crossref
Crossref
Stefan Jüttner, Michael Vieth, Stephan Miehlke, Wulf Schneider-Brachert, Christian Kirsch, Thilo Pfeuffer, Norbert Lehn & Manfred Stolte. (2004) Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in situ hybridization in formalin-fixed tissue. Modern Pathology 17:6, pages 684-689.
Crossref
Crossref
Javier P Gisbert, Sam Khorrami, Xavier Calvet & Jos?? Mar??a Pajares. (2004) Pantoprazole based therapies in Helicobacter pylori eradication. European Journal of Gastroenterology & Hepatology 16:1, pages 89-99.
Crossref
Crossref
Joachim Mössner & Karl Hans Holtermüller. 2004. Arzneiverordnungs-Report 2004. Arzneiverordnungs-Report 2004
659
684
.
Karl Hans Holtermüller. 2004. Arzneiverordnungs-Report 2003. Arzneiverordnungs-Report 2003
584
612
.
Wieslaw J. Bochenek, Suzanne Peters, Polly D. Fraga, Wenjin Wang, Michael E. Mack, Michael S. Osato, Hala M. T. El-Zimaity, Kelly D. Davis & David Y. Graham. (2003) Eradication of Helicobacter pylori by 7-Day Triple-Therapy Regimens Combining Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic Ulcer Disease: Results of Two Double-Blind, Randomized Studies. Helicobacter 8:6, pages 626-642.
Crossref
Crossref
Stephan Miehlke, Christian Kirsch, Wulf Schneider-Brachert, Christian Haferland, Michael Neumeyer, Elke Bastlein, Jens Papke, Enno Jacobs, Michael Vieth, Manfred Stolte, Norbert Lehn & Bayerdorffer Ekkehard. (2003) A Prospective, Randomized Study of Quadruple Therapy and High-Dose Dual Therapy for Treatment of Helicobacter Pylori Resistant to Both Metronidazole and Clarithromycin. Helicobacter 8:4, pages 310-319.
Crossref
Crossref
Hans-Joachim Ulmer, Andree Beckerling & Gudrun Gatz. (2003) Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of H. pylori: A Broad Data Review. Helicobacter 8:2, pages 95-104.
Crossref
Crossref
Jaime Natan Eisig, Suraia Boaventura André, Fernando Marcuz Silva, Cláudio Hashimoto, Joaquim Prado Pinto Moraes-Filho & Antonio Atilio Laudanna. (2003) The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arquivos de Gastroenterologia 40:1, pages 55-60.
Crossref
Crossref
A. Qasm, M. Buckley, H. O’Connor & C. O’Morain. 2003. Helicobactor pylori. Helicobactor pylori
503
512
.
P. Malfertheiner, U. Peitz & G. Treiber. 2003. Helicobactor pylori. Helicobactor pylori
391
400
.
Karl Hans Holtermüller. 2003. Arzneiverordnungs-Report 2002. Arzneiverordnungs-Report 2002
530
556
.
Simona Di Caro, Maria Assunta Zocco, Filippo Cremonini, Marcello Candelli, Enrico C Nista, Francesco Bartolozzi, Alessandro Armuzzi, Giovanni Cammarota, Luca Santarelli & Antonio Gasbarrini. (2002) Levofloxacin based regimens for the eradication of Helicobacter pylori. European Journal of Gastroenterology & Hepatology 14:12, pages 1309-1312.
Crossref
Crossref
A. Feydt‐Schmidt, H. Rüssmann, N. Lehn, A. Fischer, I. Antoni, D. Störk & S. Koletzko. (2002)
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin‐susceptible and clarithromycin‐resistant Helicobacter pylori
strains in gastric biopsies from children
. Alimentary Pharmacology & Therapeutics 16:12, pages 2073-2079.
Crossref
Crossref
Brian Sullivan, Walter Coyle, Richard Nemec & Thomas Dunteman. (2002) Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. The American Journal of Gastroenterology 97:10, pages 2536-2539.
Crossref
Crossref
A. Qasim & C. A. O'Morain. (2002)
Treatment of
Helicobacter pylori
infection and factors influencing eradication
. Alimentary Pharmacology & Therapeutics 16, pages 24-30.
Crossref
Crossref
U. Peitz, M. Sulliga, K. Wolle, A. Leodolter, U. Von Arnim, S. Kahl, M. Stolte, G. Börsch, J. Labenz & P. Malfertheiner. (2002)
High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure
Helicobacter pylori
infection: impact of two second‐line therapies in a randomized study
. Alimentary Pharmacology & Therapeutics 16:2, pages 315-324.
Crossref
Crossref
F. Bazzoli, G. Bianchi Porro, G. Maconi, M. Molteni, P. Pozzato & R.M. Zagari. (2002) Treatment of Helicobacter pylori infection. indications and regimens: an update. Digestive and Liver Disease 34:1, pages 70-83.
Crossref
Crossref
Patrick Bontems, Jeanne-Marie Devaster, Luigi Corvaglia, Antal Dezsöfi, Chantal van den Borre, Sylvianne Goutier, Jean-Paul Butzler & Samy Cadranel. (2001) Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. The Pediatric Infectious Disease Journal 20:11, pages 1033-1038.
Crossref
Crossref
M. J. R. Janssen, A. H. A. M. Van Oijen, A. L. M. Verbeek, J. B. M. J. Jansen & W. A. De Boer. (2002)
A systematic comparison of triple therapies for treatment of
Helicobacter pylori
infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole
. Alimentary Pharmacology & Therapeutics 15:5, pages 613-624.
Crossref
Crossref
R. Walter. 2001.
283
313
.
Karl Hans Holtermüller. 2001. Arzneiverordnungs-Report 2000. Arzneiverordnungs-Report 2000
455
481
.
A Pilotto, M Rassu, G Leandro, M Franceschi & F Di Mario. (2000) Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. Digestive and Liver Disease 32:9, pages 763-768.
Crossref
Crossref
F. Bazzoli, L. Olivieri, L. De Luca, P. Pozzato, P. Lehours & F. Megraud. (2000) Therapy and drug resistance in Helicobacter pylori infection. Digestive and Liver Disease 32, pages 207-210.
Crossref
Crossref
A. Pilotto, M. Franceschi, M. Rassu, G. Leandro, L. Bozzola, F. Furlan & F. Di Mario. (2000) Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Digestive and Liver Disease 32:8, pages 667-672.
Crossref
Crossref